Milestone Pharmaceuticals Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $18.1M | $14.4M | $31.1M | $39.8M | $38.7M | $34.5M | $42.0M |
| SG&A Expense | — | $17.3M | $16.7M | $15.9M | $15.7M | $12.4M | $10.3M | $7.0M |
| Operating Income | — | $-62.1M | $-42.1M | $-61.1M | $-59.6M | $-43.1M | $-50.7M | $-57.9M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | $2.6M | — | — | — | — |
| Pretax Income | — | $-63.1M | $-41.5M | $-59.7M | $-58.4M | $-42.9M | $-50.0M | $-55.3M |
| Income Tax Expense | — | — | — | — | — | — | $-17.0K | $-56.0K |
| Net Income | — | $-63.1M | $-41.5M | $-59.7M | $-58.4M | $-42.9M | $-50.0M | $-55.2M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.75 | $-0.67 | $-1.39 | $-1.38 | $-1.02 | $-1.70 | $-3.50 |
| EPS (Diluted) | — | $-0.75 | $-0.67 | $-1.39 | $-1.38 | $-1.02 | $-1.70 | $-3.50 |
| Shares Outstanding (Basic) | 117.7M | 106.2M | 53.4M | 33.5M | 34.3M | 29.9M | 29.8M | 24.5M |
| Shares Outstanding (Diluted) | 117.7M | 106.2M | 53.4M | 33.5M | 34.3M | 29.9M | 29.8M | 24.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |